Robert W. Baird assumed coverage on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a report issued on Wednesday morning, MarketBeat reports. The firm issued a neutral rating and a $15.00 price target on the biopharmaceutical company’s stock. Several other brokerages have also recently commented on SAGE. Truist Financial reduced their target price on […]
Baird R W upgraded shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports. A number of other analysts have also weighed in on the company. Wedbush reaffirmed a neutral rating and set a $24.00 price objective on shares of Sage Therapeutics […]
Sage Therapeutics (NASDAQ:SAGE) Trading Down 4.2% theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Sage Therapeutics (NASDAQ:SAGE) Given New $28.00 Price Target at JPMorgan Chase & Co. themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Sage Therapeutics (NASDAQ:SAGE – Free Report) had its target price cut by Royal Bank of Canada from $26.00 to $15.00 in a report released on Friday morning, Benzinga reports. They currently have a sector perform rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued reports about the stock. Oppenheimer reduced their […]